Art

J-GLOBAL ID：201502219869518280   Reference number：15A0194548

Efficacy of Molecular Response at 1 or 3 Months after the Initiation of Dasatinib Treatment Can Predict an Improved Response to Dasatinib in Imatinib-Resistant or Imatinib-Intolerant Japanese Patients with Chronic Myelogenous Leukemia during the Chronic Phase

ダサチニブ治療開始後1カ月あるいは3カ月の分子学的反応の効果はイマチニブ抵抗性あるいはイマチニブ不耐の慢性期慢性骨髄性白血病の日本人患者におけるダサチニブへの反応改善を予測できる

Author (18)： INOKUCHI Koiti (Div. of Hematology, Dep. of Internal Medicine, Nippon Medical School) ,  KUMAGAI Takashi (Dep. of Hematology, Ohme Municipal General Hospital) ,  MATSUKI Eri (Div. of Hematology, Dep. of Internal Medicine, Keio Univ. School of Medicine) ,  OHASHI Kazuteru (Hematology Div., Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital) ,  SHINAGAWA Atsushi (Dep. of Internal Medicine, Hitachi General Hospital) ,  HATTA Yoshihiro (Dep. of Hematology and Rheumatology, Nihon Univ. School of Medicine) ,  TAKEUCHI Jin (Dep. of Hematology and Rheumatology, Nihon Univ. School of Medicine) ,  YOSHIDA Chikashi (Dep. of Hematology, National Hospital Organization Mito Medical Center) ,  WAKITA Hisashi (Div. of Hematology and Oncology, Japanese Red Cross Soc., Narita Red Cross Hospital) ,  KOZAI Yasuji (Dep. of Hematology, Tokyo Metropolitan Tama Medical Center) ,  SHIRASUGI Yukari (Div. of Hematology, Dep. of Internal Medicine, Tokai Univ. School of Medicine) ,  FUJISAWA Shin (Dep. of Hematology, Yokohama City Univ. Medical Center) ,  IWASE Osamu (Div. of Hematology, Hachioji Medical Center, Tokyo Medical Univ.) ,  YANO Shingo (Div. of Clinical Oncology and Hematology, Dep. of Internal Medicine, Jikei Univ. School of Medicine) ,  OKAMOTO Shinichiro (Div. of Hematology, Dep. of Internal Medicine, Keio Univ. School of Medicine) ,  OBA Koji (Interfaculty Initiative in Information Studies, The Univ. of Tokyo, Tokyo, Japan & Dep. of Biostatistics, School of ...) ,  SAKAMOTO Junichi (Tokai Central Hospital) ,  SAKAMAKI Hisashi (Hematology Div., Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital)
Material： Journal of Clinical and Experimental Hematopathology  (J Clin Exp Hematop)
Volume： 54  Issue： 3  Page： 197-204 (J-STAGE)  Publication year： 2014 
JST Material Number： L4611A  ISSN： 1346-4280  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： human(primates) ,...
Semi thesaurus term： BCR-ABL ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=15A0194548&from=J-GLOBAL&jstjournalNo=L4611A") }}

JST classification (2)： Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Blood cell tumors(=neoplasms)  (GK04000M)

Substance index (1)： Dasatinib

Reference (30)：

• 1 Wong S, Witte ON: The BCR-ABL story: bench to bedside and back. Annu Rev Immunol 22:247-306, 2004
• 2 Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042, 2001
• 3 Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
• 4 Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, et al.: Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res 8:2167-2176, 2002
• 5 Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, et al.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417, 2006

Terms in the title (9)： ダサチニブ ,  治療 ,  分子 ,  イマチニブ ,  抵抗性 ,  慢性期慢性骨髄性白血病 ,  日本人 ,  患者 ,  予測